TGFBR1 and neoplasm: Furthermore, previous reports demonstrate that systemic administration of a TGF-βR1 inhibitor (Calbiochem: LY364947) increases tumor vessel permeability [44] and smad4 deficient mice exhibit defects in vascular integrity and maturation as well as abnormal gap junction formation [45].